Myc suppression of Nfkb2 accelerates lymphomagenesis

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Keller, Ulrich ^a,b   Huber, Jürgen ^a   Nilsson, Jonas A ^b,c   Fallahi, Mohammad ^d   Hall, Mark A ^b,d   Peschel, Christian ^a   Cleveland, John L ^b,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; TRANSCRIPTION FACTOR NFKB2; UNCLASSIFIED DRUG; MESSENGER RNA; MYC PROTEIN, HUMAN; MYC PROTEIN, MOUSE; NFKB2 PROTEIN, HUMAN; NFKB2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; FIBROBLAST; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENE LOSS; GENE REPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOMAGENESIS; MOUSE; NONHUMAN; PRECANCER; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; TUMOR PROMOTION; ANIMAL; C57BL MOUSE; CELL CULTURE; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PROMOTER REGION; TIME;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BURKITT LYMPHOMA; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NF-KAPPA B P52 SUBUNIT; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 77954058175     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-348     Document Type: Article

References (54)

1. Gilmore TD. Introduction to NF-κB: players, pathways, perspectives. Oncogene 2006, 25(51):6680-6684. 10.1038/sj.onc.1209954, 17072321.
2. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004, 18(18):2195-2224. 10.1101/gad.1228704, 15371334.
3. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002, 109(Suppl):S81-96. 10.1016/S0092-8674(02)00703-1, 11983155.
4. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, et al. Activation by IKKα of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293(5534):1495-1499. 10.1126/science.1062677, 11520989.
5. Xiao G, Harhaj EW, Sun SC. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell 2001, 7(2):401-409. 10.1016/S1097-2765(01)00187-3, 11239468.
6. Caamano JH, Rizzo CA, Durham SK, Barton DS, Raventos-Suarez C, Snapper CM, Bravo R. Nuclear factor (NF)- κB2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med 1998, 187(2):185-196. 10.1084/jem.187.2.185, 2212102, 9432976.
7. Orlowski RZ, Baldwin AS. NF-κB as a therapeutic target in cancer. Trends Mol Med 2002, 8(8):385-389. 10.1016/S1471-4914(02)02375-4, 12127724.
8. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2(4):301-310. 10.1038/nrc780, 12001991.
9. Courtois G, Gilmore TD. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene 2006, 25(51):6831-6843. 10.1038/sj.onc.1209939, 17072331.
10. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18(49):6938-6947. 10.1038/sj.onc.1203221, 10602468.
11. Perkins ND. Oncogenes, tumor suppressors and p52 NF-κB. Oncogene 2003, 22(48):7553-7556. 10.1038/sj.onc.1207139, 14576816.
12. Chang CC, Zhang J, Lombardi L, Neri A, Dalla-Favera R. Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. Mol Cell Biol 1995, 15(9):5180-5187. 230765, 7651435.
13. Kim KE, Gu C, Thakur S, Vieira E, Lin JC, Rabson AB. Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes. Oncogene 2000, 19(10):1334-1345. 10.1038/sj.onc.1203432, 10713675.
14. Ishikawa H, Carrasco D, Claudio E, Ryseck RP, Bravo R. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2. J Exp Med 1997, 186(7):999-1014. 10.1084/jem.186.7.999, 2199059, 9314550.
15. Sheiness D, Fanshier L, Bishop JM. Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29. J Virol 1978, 28(2):600-610. 354308, 214581.
16. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001, 20(40):5595-5610. 10.1038/sj.onc.1204595, 11607812.
17. Kelly K, Cochran BH, Stiles CD, Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983, 35(3 Pt 2):603-610. 10.1016/0092-8674(83)90092-2, 6606489.
18. Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 1996, 68:109-182. full_text, 8712067.
19. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003, 22(56):9007-9021. 10.1038/sj.onc.1207261, 14663479.
20. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000, 16:653-699. 10.1146/annurev.cellbio.16.1.653, 11031250.
21. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006, 354(23):2431-2442. 10.1056/NEJMoa055759, 16760443.
22. Keller U, Nilsson JA, Maclean KH, Old JB, Cleveland JL. Nfkb 1 is dispensable for Myc-induced lymphomagenesis. Oncogene 2005, 24(41):6231-6240. 10.1038/sj.onc.1208779, 15940251.
23. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318(6046):533-538. 10.1038/318533a0, 3906410.
24. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes & development 1999, 13(20):2658-2669. 317106, 10541552, 10.1101/gad.13.20.2658.
25. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes & development 1998, 12(15):2424-2433. 317045, 9694806, 10.1101/gad.12.15.2424.
26. Pajic A, Spitkovsky D, Christoph B, Kempkes B, Schuhmacher M, Staege MS, Brielmeier M, Ellwart J, Kohlhuber F, Bornkamm GW, et al. Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer 2000, 87(6):787-793. 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6, 10956386.
27. Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, Aslanian A, Lees JA, Sherr CJ, Roussel MF, Cleveland JL. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell 2003, 11(4):905-914. 10.1016/S1097-2765(03)00102-3, 12718877.
28. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes & development 2001, 15(16):2069-2082. 312758, 11511539, 10.1101/gad.906601.
29. Lewis BC, Shim H, Li Q, Wu CS, Lee LA, Maity A, Dang CV. Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Molecular and cellular biology 1997, 17(9):4967-4978. 232348, 9271375.
30. Keller UB, Old JB, Dorsey FC, Nilsson JA, Nilsson L, Maclean KH, Chung L, Yang C, Spruck C, Boyd K, et al. Myc targets Cks1 to provoke the suppression of p27(Kip1), proliferation and lymphomagenesis. Embo J 2007, 26(10):2562-2574. 10.1038/sj.emboj.7601691, 1868903, 17464290.
31. Liptay S, Schmid RM, Nabel EG, Nabel GJ. Transcriptional regulation of NF-κB2: evidence for κB-mediated positive and negative autoregulation. Molecular and cellular biology 1994, 14(12):7695-7703. 359311, 7969113.
32. Oswald F, Liptay S, Adler G, Schmid RM. NF-κB2 is a putative target gene of activated Notch-1 via RBP-Jκ. Mol Cell Biol 1998, 18(4):2077-2088. 121438, 9528780.
33. Qing G, Xiao G. Essential role of IκB kinase-α in the constitutive processing of NF-κB2 p100. The Journal of biological chemistry 2005, 280(11):9765-9768. 10.1074/jbc.C400502200, 15677466.
34. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic acids research 1995, 23(10):1686-1690. 10.1093/nar/23.10.1686, 306922, 7784172.
35. Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, Eilers M. An alternative pathway for gene regulation by Myc. Embo J 1997, 16(18):5672-5686. 10.1093/emboj/16.18.5672, 1170199, 9312026.
36. Wanzel M, Herold S, Eilers M. Transcriptional repression by Myc. Trends Cell Biol 2003, 13(3):146-150. 10.1016/S0962-8924(03)00003-5, 12628347.
37. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, Moroy T, Bartek J, Massague J, Hanel F, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001, 3(4):392-399. 10.1038/35070076, 11283613.
38. Wu S, Cetinkaya C, Munoz-Alonso MJ, von der Lehr N, Bahram F, Beuger V, Eilers M, Leon J, Larsson LG. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 2003, 22(3):351-360. 10.1038/sj.onc.1206145, 12545156.
39. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999, 13(20):2670-2677. 10.1101/gad.13.20.2670, 317110, 10541553.
40. Old JB, Kratzat S, Hoellein A, Graf S, Nilsson JA, Nilsson L, Nakayama KI, Peschel C, Cleveland JL, Keller UB. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis. Mol Cancer Res 2010, 8(3):353-362. 10.1158/1541-7786.MCR-09-0232, 20197382.
41. Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, Nilsson LM, Neale G, Kramer DL, Porter CW, et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 2005, 7(5):433-444. 10.1016/j.ccr.2005.03.036, 15894264.
42. Perkins ND. NF-κB: tumor promoter or suppressor?. Trends Cell Biol 2004, 14(2):64-69. 10.1016/j.tcb.2003.12.004, 15102437.
43. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006, 354(23):2419-2430. 10.1056/NEJMoa055351, 16760442.
44. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005, 6(8):635-645. 10.1038/nrm1703, 16064138.
45. Lee LA, Dang CV. Myc target transcriptomes. Curr Top Microbiol Immunol 2006, 302:145-167. full_text, 16620028.
46. Gartel AL, Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res 2003, 283(1):17-21. 10.1016/S0014-4827(02)00020-4, 12565816.
47. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, Golub TR. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 2000, 97(7):3260-3265. 10.1073/pnas.97.7.3260, 16226, 10737792.
48. Bush A, Mateyak M, Dugan K, Obaya A, Adachi S, Sedivy J, Cole M. c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets. Genes Dev 1998, 12(24):3797-3802. 10.1101/gad.12.24.3797, 317273, 9869632.
49. de Alboran IM, O'Hagan RC, Gartner F, Malynn B, Davidson L, Rickert R, Rajewsky K, DePinho RA, Alt FW. Analysis of c-MYC function in normal cells via conditional gene-targeted mutation. Immunity 2001, 14(1):45-55. 10.1016/S1074-7613(01)00088-7, 11163229.
50. Homig-Holzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Muller W, Quintanilla-Martinez L, Gewies A, Ruland J, Rajewsky K, et al. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis. J Exp Med 2008, 205(6):1317-1329. 10.1084/jem.20080238, 2413030, 18490492.
51. Wang Z, Zhang B, Yang L, Ding J, Ding HF. Constitutive production of NF-κB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression. J Biol Chem 2008, 283(16):10698-10706. 10.1074/jbc.M800806200, 18281283.
52. Zhang B, Wang Z, Li T, Tsitsikov EN, Ding HF. NF-κB2 mutation targets TRAF1 to induce lymphomagenesis. Blood 2007, 110(2):743-751. 10.1182/blood-2006-11-058446, 1924489, 17405906.
53. Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T. The IKK2/NF-κB pathway suppresses MYC-induced lymphomagenesis. Blood 2009, 114(12):2448-2458. 10.1182/blood-2008-09-181008, 19628709.
54. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romieu-Mourez R, et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 2001, 20(14):1688-1702. 10.1038/sj.onc.1204245, 11313917.